Solventum Q4 sales beat estimates

Reuters02-27 05:52

<a href="https://laohu8.com/S/SOLV">Solventum</a> Q4 sales beat estimates

Overview

Healthcare solutions provider's Q4 sales beat analyst expectations
Adjusted EPS for Q4 beat analyst expectations

Outlook

Solventum expects full-year 2026 organic sales growth of 2.0% to 3.0%
Company projects 2026 adjusted EPS between $6.40 and $6.60
Solventum anticipates free cash flow of ~$200 mln for 2026

Result Drivers

ORGANIC SALES GROWTH - Driven by strong performance in Infection Prevention and Surgical Solutions and Dental Solutions segments
DIVESTITURE IMPACT - Debt paydown from Purification and Filtration sale boosted adjusted EPS

Company press release: ID:nPn4mCZkBa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 sales	Beat	$2 bln	$1.96 bln (10 Analysts)
Q4 Adjusted EPS	Beat	$1.57	$1.50 (11 Analysts)
Q4 EPS		$0.36
Q4 Net Income		$63 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Solventum Corp is $97.00, about 29.2% above its February 25 closing price of $75.08
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614071065?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 05:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614071065","market":"us","top_or_hot":-1,"title":"Solventum Q4 sales beat estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/SOLV\">Solventum</a> Q4 sales beat estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Healthcare solutions provider's Q4 sales beat analyst expectations</p></li><li><p>Adjusted EPS for Q4 beat analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Solventum expects full-year 2026 organic sales growth of 2.0% to 3.0%</p></li><li><p>Company projects 2026 adjusted EPS between $6.40 and $6.60</p></li><li><p>Solventum anticipates free cash flow of ~$200 mln for 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ORGANIC SALES GROWTH - Driven by strong performance in Infection Prevention and Surgical Solutions and Dental Solutions segments</p></li><li><p>DIVESTITURE IMPACT - Debt paydown from Purification and Filtration sale boosted adjusted EPS</p></li></ul><p>Company press release: <span>ID:nPn4mCZkBa</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 sales</p></td><td><p>Beat</p></td><td><p>$2 bln</p></td><td><p>$1.96 bln (10 Analysts)</p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>$1.57</p></td><td><p>$1.50 (11 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>$0.36</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>$63 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 7 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Solventum Corp is $97.00, about 29.2% above its February 25 closing price of $75.08</p></li><li><p>The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Solventum Q4 sales beat estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSolventum Q4 sales beat estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-27 05:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/SOLV\">Solventum</a> Q4 sales beat estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Healthcare solutions provider's Q4 sales beat analyst expectations</p></li><li><p>Adjusted EPS for Q4 beat analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Solventum expects full-year 2026 organic sales growth of 2.0% to 3.0%</p></li><li><p>Company projects 2026 adjusted EPS between $6.40 and $6.60</p></li><li><p>Solventum anticipates free cash flow of ~$200 mln for 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ORGANIC SALES GROWTH - Driven by strong performance in Infection Prevention and Surgical Solutions and Dental Solutions segments</p></li><li><p>DIVESTITURE IMPACT - Debt paydown from Purification and Filtration sale boosted adjusted EPS</p></li></ul><p>Company press release: <span>ID:nPn4mCZkBa</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 sales</p></td><td><p>Beat</p></td><td><p>$2 bln</p></td><td><p>$1.96 bln (10 Analysts)</p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>$1.57</p></td><td><p>$1.50 (11 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>$0.36</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>$63 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 7 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Solventum Corp is $97.00, about 29.2% above its February 25 closing price of $75.08</p></li><li><p>The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL1N3ZM1HR:1","article_id":"2614071065","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614071065","pubTimestamp":1772142776,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Solventum Q4 sales beat estimatesOverviewHealthcare solutions provider's Q4 sales beat analyst expectationsAdjusted EPS for Q4 beat analyst expectationsOutlookSolventum expects full-year 2026 organic ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","SOLV":"Solventum"},"translate_title":"Solventum第四季度销售额超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SOLV":0.9},"content_text":"Solventum Q4 sales beat estimatesOverviewHealthcare solutions provider's Q4 sales beat analyst expectationsAdjusted EPS for Q4 beat analyst expectationsOutlookSolventum expects full-year 2026 organic sales growth of 2.0% to 3.0%Company projects 2026 adjusted EPS between $6.40 and $6.60Solventum anticipates free cash flow of ~$200 mln for 2026Result DriversORGANIC SALES GROWTH - Driven by strong performance in Infection Prevention and Surgical Solutions and Dental Solutions segmentsDIVESTITURE IMPACT - Debt paydown from Purification and Filtration sale boosted adjusted EPSCompany press release: ID:nPn4mCZkBaKey DetailsMetricBeat/MissActualConsensus EstimateQ4 salesBeat$2 bln$1.96 bln (10 Analysts)Q4 Adjusted EPSBeat$1.57$1.50 (11 Analysts)Q4 EPS$0.36Q4 Net Income$63 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 7 \"hold\" and 1 \"sell\" or \"strong sell\"The average consensus recommendation for the medical equipment, supplies & distribution peer group is \"buy\"Wall Street's median 12-month price target for Solventum Corp is $97.00, about 29.2% above its February 25 closing price of $75.08The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months agoFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614071065","isCrawlerRequest":true}